Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
The ECHELON-2 trial: Results of a randomised, double-blind, active-controlled phase 3 study of brentuximab vedotin and CHP (A plus CHP) vs CHOP in the frontline treatment of patients (pts) with CD30(+) peripheral T-cell lymphomas (PTCLs)
The ECHELON-2 trial: Results of a randomised, double-blind, active-controlled phase 3 study of brentuximab vedotin and CHP (A plus CHP) vs CHOP in the frontline treatment of patients (pts) with CD30(+) peripheral T-cell lymphomas (PTCLs) Truemper, L., O'Connor, O. A., Pro, B., Illidge, T. M., Advani, R. H., Bartlett, N. L., Christensen, H. J., Morschhauser, F., Domingo-Domenech, E., Rossi, G., Kim, W. S., Feldman, T. A., Lennard, A., Belada, D., Illes, A., Tobinai, K., Tsukasaki, K., Yeh, S., Shustov, A. R., Huettmann, A., Savage, K. J., Yuen, S., Iyer, S., Zinzani, P. L., Hua, Z., Little, M., Rao, S., Woolery, J., Manley, T., Horwitz, S. M. KARGER. 2019: 23View details for Web of Science ID 000568159600053